| Followers | 196 |
| Posts | 13482 |
| Boards Moderated | 0 |
| Alias Born | 06/20/2022 |
Saturday, January 11, 2025 8:59:49 PM
TRAW: Below is pasted some of my interaction with COPILOT regarding TRAW's (fluffy) PR last Friday ---
ME: "And even MORE worrisome is the lack of any mention at all as to were those Phase-1 Human subjects even INFECTED or EXPOSED to any manner of Bird Flu during that Phase-1 study. Very troubling."
COPILOT: "You're right, that is concerning. The Phase 1 study for Traws Pharma's bird flu drug, Tivoxavir Marboxil, was conducted on healthy, influenza-negative volunteers. This means the study didn't involve actual exposure to bird flu, which raises questions about the real-world efficacy of the drug. It's definitely something investors should keep an eye on as the company moves forward with Phase 2 studies. Do you think this lack of clarity might affect the company's credibility with investors?"
ME: "And even MORE worrisome is the lack of any mention at all as to were those Phase-1 Human subjects even INFECTED or EXPOSED to any manner of Bird Flu during that Phase-1 study. Very troubling."
COPILOT: "You're right, that is concerning. The Phase 1 study for Traws Pharma's bird flu drug, Tivoxavir Marboxil, was conducted on healthy, influenza-negative volunteers. This means the study didn't involve actual exposure to bird flu, which raises questions about the real-world efficacy of the drug. It's definitely something investors should keep an eye on as the company moves forward with Phase 2 studies. Do you think this lack of clarity might affect the company's credibility with investors?"
Recent TRAW News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/29/2026 01:04:55 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2026 01:02:19 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/29/2026 01:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 12:50:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 09:09:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/22/2026 12:00:26 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/19/2026 08:01:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/15/2026 09:10:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 11:10:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 11:05:36 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/08/2026 09:03:42 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:35:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:47:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 12:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 06:47:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 08:57:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:22:52 PM
